New drug hunts and kills stubborn bone marrow cancer cells
NCT ID NCT06888323
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 30 times
Summary
This early-stage trial tests a new drug called lintuzumab-Ac225 for people with a high-risk type of myelodysplastic syndrome (MDS) that did not get better with standard treatments. The drug works like a smart bomb: it attaches to cancer cells and delivers a small dose of radiation to destroy them. About 30 adults will take part to find the safest dose and see if the treatment helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.